This trial will test whether the medication brexpiprazole (BREX) can help reduce drinking in people with Alcohol Use Disorder (AUD), and whether this effect is influenced by genetic variation in the gene encoding the dopamine transporter (DAT1).
3 Primary · 0 Secondary · Reporting Duration: 14 days - change between baseline and day 14 scan.
250 Total Participants · 3 Treatment Groups
Primary Treatment: BREX 2mg · Has Placebo Group · Phase 2
Age 21 - 65 · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: